The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Correlation of Interleukin-6 of Pancreatic Cancer Patients and Cancer Progression: Case Series

췌장암 환자의 IL-6 수치와 암 진행의 상관 관계에 대한 3례 증례보고

  • Han-eum Joo (East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Young-min Cho (East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Jun-yeol Kim (East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Jung-hyang Park (East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Soo-jin Kim (East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) ;
  • Hae-chang Yoon (Dept. of Public Health, Graduate School, Kyungpook National University) ;
  • Jung-hyo Cho (East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
  • 주한음 (대전대학교 대전한방병원 동서암센터) ;
  • 조영민 (대전대학교 대전한방병원 동서암센터) ;
  • 김준열 (대전대학교 대전한방병원 동서암센터) ;
  • 박정향 (대전대학교 대전한방병원 동서암센터) ;
  • 김수진 (대전대학교 대전한방병원 동서암센터) ;
  • 윤해창 (경북대학교 일반대학원 보건학과) ;
  • 조정효 (대전대학교 대전한방병원 동서암센터)
  • Received : 2024.05.28
  • Accepted : 2024.07.01
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To report a correlation of IL-6 of pancreatic cancer and cancer progression in three pancreatic cancer patients. Method: Three pancreatic cancer patients were monitored for changes in IL-6 levels, tumor markers (CEA, CA19-9), and clinical outcomes over their treatment period. Results: Patient 1's IL-6 levels rose with liver metastasis and tumor progression, coinciding with increases in tumor markers. Patient 2's IL-6 levels remained elevated during chemotherapy, correlating with tumor growth. Patient 3's IL-6 levels spiked prior to cancer progression. Conclusion: Elevated IL-6 levels were observed in advancing pancreatic cancer patients, suggesting IL-6 as a potential biomarker for monitoring cancer progression in pancreatic cancer. Regular IL-6 monitoring could improve prognostic evaluations and treatment strategies.

Keywords

References

  1. Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2020. Sejong: Ministry of Health and Welfare; 2020, p. 1-52. 
  2. National Health Insurance Service, Health Insurance Review & Assessment Service, "Health Insurance Statistics", 2024 Q1, May 25, 2024, Status of Medical Institutions by Establishment Type. 
  3. Gal P, Brabek J, Holub M, Jakubek M, Sedo A, Lacina L, et al. Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. Histochem Cell Biol 2022;158(5):415-34.  https://doi.org/10.1007/s00418-022-02140-x
  4. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol 2016 Sep;37(9):11553-72.  https://doi.org/10.1007/s13277-016-5098-7
  5. Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol 2019;10(3):537-45.  https://doi.org/10.21037/jgo.2019.01.09
  6. Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 2018;108:1415-24.  https://doi.org/10.1016/j.biopha.2018.09.177
  7. Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005;8(2):124-31.  https://doi.org/10.1007/s10120-005-0315-x
  8. Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev Immunol 1985;3:133-57.  https://doi.org/10.1146/annurev.iy.03.040185.001025
  9. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb Perspect Biol 2014;6(10):a016295-a. 
  10. Briukhovetska D, Dorr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021;21(8):481-99.  https://doi.org/10.1038/s41568-021-00363-z
  11. Raskova M, Lacina L, Kejik Z, Venhauerova A, Skalickova M, Kolar M, et al. The Role of IL-6 in Cancer Invasiveness and Metastasis-Overview and Therapeutic Opportunities. Cells 2022;11(22):3698. 
  12. Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, et al. Interleukin-6 Is Required for Pancreatic Cancer Progression by Promoting MAPK Signaling Activation and Oxidative Stress Resistance. Cancer Res 2013 Oct;72(20):6359-74.  https://doi.org/10.1158/0008-5472.CAN-13-1558-T
  13. Van Duijneveldt G, Michael, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134(16):2091-115.  https://doi.org/10.1042/CS20191211
  14. Kim HW, Lee JC, Paik KH, Kang J, Kim J, Hwang JH. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore) 2017;96(5):e5926.